Jeff Garro
Stock Analyst at Stephens & Co.
(0.79)
# 4,005
Out of 5,182 analysts
62
Total ratings
30%
Success rate
-13.5%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Maintains: Equal-Weight | $20 → $18 | $23.25 | -22.58% | 4 | Apr 1, 2026 | |
| PHR Phreesia | Maintains: Overweight | $32 → $20 | $9.17 | +118.10% | 10 | Mar 31, 2026 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $3.5 → $2 | $1.32 | +51.52% | 5 | Mar 13, 2026 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $17 → $10 | $7.17 | +39.47% | 5 | Mar 6, 2026 | |
| DH Definitive Healthcare | Maintains: Equal-Weight | $3 → $2 | $1.03 | +94.17% | 2 | Feb 27, 2026 | |
| CERT Certara | Maintains: Overweight | $15 → $12 | $6.22 | +92.93% | 6 | Dec 12, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $32 | $24.02 | +33.22% | 6 | Dec 4, 2025 | |
| EVH Evolent Health | Reiterates: Equal-Weight | $9 | $2.84 | +216.90% | 6 | Sep 24, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $28 → $20 | $14.37 | +39.18% | 2 | Jul 15, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $167.95 | +66.72% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $55 | $24.71 | +122.58% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $250 | $176.46 | +41.68% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $15.75 | +7.94% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $5.69 | +392.09% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $21.22 | -5.75% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $8.24 | -52.67% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.78 | +285.70% | 3 | May 6, 2022 |
TruBridge
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $20 → $18
Current: $23.25
Upside: -22.58%
Phreesia
Mar 31, 2026
Maintains: Overweight
Price Target: $32 → $20
Current: $9.17
Upside: +118.10%
Health Catalyst
Mar 13, 2026
Maintains: Equal-Weight
Price Target: $3.5 → $2
Current: $1.32
Upside: +51.52%
OptimizeRx
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $7.17
Upside: +39.47%
Definitive Healthcare
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.03
Upside: +94.17%
Certara
Dec 12, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $6.22
Upside: +92.93%
Privia Health Group
Dec 4, 2025
Reiterates: Overweight
Price Target: $32
Current: $24.02
Upside: +33.22%
Evolent Health
Sep 24, 2025
Reiterates: Equal-Weight
Price Target: $9
Current: $2.84
Upside: +216.90%
Simulations Plus
Jul 15, 2025
Maintains: Overweight
Price Target: $28 → $20
Current: $14.37
Upside: +39.18%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $167.95
Upside: +66.72%
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $24.71
Upside: +122.58%
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $176.46
Upside: +41.68%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $15.75
Upside: +7.94%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $5.69
Upside: +392.09%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $21.22
Upside: -5.75%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $8.24
Upside: -52.67%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $0.78
Upside: +285.70%